New quarterly report expected Apr 27, 2026. Report will refresh after results.
C
CNO Financial Group, Inc.
CNO · Financial Services
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
Cheap Float, Expensive Tail: CNO's Demographic Bet Carries a Hidden Actuarial Grenade
The market is treating CNO as a value stock discounted for slow growth, but the real question isn't the multiple — it's whether the long-term care reserve assumption embedded in that FCF yield is honest, because every insurer that wrote LTC aggressively has eventually discovered the assumptions weren't.
Flowly Score
Apr 16 Close
+109%$42.98
Fair Value
$90.00
49
Below Averageat $42.98
Business Strength5/10
A genuinely specialized franchise serving a growing demographic niche, but the moat is narrowing — ROIC barely above zero tells you the business earns almost nothing on incremental capital, and the agent-distribution model faces quiet structural erosion from digital comparison shopping. Not broken, but not compounding.
Financial Resilience6/10
The cash conversion quality is real — operating cash consistently exceeds reported earnings, capex is essentially zero, and the FCF stream has been remarkably stable across multiple economic environments. The concern is the debt load matching the entire market cap, and the abrupt 2025 halt in buybacks signals something has shifted in capital management thinking.
Growth & Trajectory4/10
Buybacks are doing the growth heavy lifting — EPS outpaces net income precisely because the share count is shrinking, not because the underlying business is compounding. Flat revenue and collapsing net margins in 2025 suggest the demographic tailwind and the actuarial headwind are currently fighting to a draw, with the headwind winning.
Valuation7/10at $39.87
A FCF yield north of 16% for a business this predictable is genuinely unusual — the market is pricing in a scenario where the LTC tail bites and compounding stalls, but even the pessimistic DCF scenario implies the stock is materially cheap. The margin of safety is real; the question is what it's protecting against.
Risk4/10
Three specific risks converge here: legacy long-term care reserve adequacy is a tail that has destroyed capital at similar insurers with almost no warning; agent-based distribution is a decades-built asset being commoditized by digital enrollment platforms; and debt equal to the entire market cap means a reserve charge doesn't just hurt earnings — it threatens the capital structure itself.
CNO is genuinely cheap on cash generation — a stable, recurring, asset-light business producing FCF at a yield that most quality compounders haven't seen in years. The demographic logic is sound: eleven thousand Americans turning sixty-five daily is not a thesis that requires a spreadsheet. Management has been unusually disciplined for an insurance holding company, returning capital systematically and resisting the acquisition temptation that destroyed the predecessor entity. All of that is real, and at current prices, you're buying it at a meaningful discount to what the business would be worth if the actuarial book is clean. The trajectory concern is structural, not cyclical. Margin compression in 2025 isn't just a bad year — it's the signal that the spread between what CNO collects and what it pays is thinning as older, expensive legacy business runs off and new business faces more competitive pricing. Medicare Supplement's 2025 resurgence is a genuine tailwind as Medicare Advantage carriers retreat, but it's also worth asking whether that tailwind reshuffles customers CNO was already winning through Bankers Life agents or opens genuinely new addressable market. The agent network itself is the moat you're renting — and digital-first competitors are building cheaper distribution every quarter. The single biggest risk is the long-term care runoff book, and it cannot be stress-tested from the outside. LTC reserve adequacy depends on assumptions about how long policyholders live and how intensively they use care — assumptions that have proven systematically optimistic across the entire insurance industry for decades. CNO has been de-risking this book deliberately, which is the right move, but 'de-risking' and 'resolved' are not the same thing. A material reserve strengthening charge — the kind that surfaces after an actuarial review, not a business downturn — could erase multiple years of FCF in a single quarter, force suspended buybacks, and potentially require capital at precisely the moment the stock is under maximum pressure.